Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RASGRF1
REST API REST API
Homo sapiens
RASGRF1 is differentially expressed in 239 experiments: 146 organism parts: amygdala, cerebellum, ... (144 more);, 180 disease states: normal, lung adenocarcinoma, ... (178 more);, 62 cell types 316 cell lines 27 compound treatments and 72 other conditions.
Synonyms GRF55, CDC25, GRF1, GNRP, H-GRF55, PP13187, CDC25L
Orthologs CDC25 (Saccharomyces cerevisiae)   RASGRF1 (Danio rerio)   Rasgrf1 (Mus musculus)   RASGRF1 (Bos taurus)   RASGRF1 (Gallus gallus)   Rasgrf1 (Rattus norvegicus)   rasgrf1 (Xenopus laevis)   RASGRF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cell proliferation, intracellular, regulation of Rho protein signal transduction, guanyl-nucleotide exchange factor activity, regulation of Ras protein signal transduction, small GTPase mediated signal transduction, neuron projection development, regulation of small GTPase mediated signal transduction, Rho guanyl-nucleotide exchange factor activity, growth cone, activation of Rac GTPase activity, regulation of neuronal synaptic plasticity, regulation of Rac protein signal transduction, positive regulation of Ras GTPase activity, glutamate receptor binding
InterPro Term Ras-like_Gua-exchang_fac_N, Pleckstrin_homology, RasGRF_CDC25, DH-domain, IQ_motif_EF-hand-BS
UniProt Accession Q13972, F8VPA5
Search EB-eye ENSG00000058335
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (34 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-MTAB-37, E-GEOD-18005, E-GEOD-2509
H441
2
E-GEOD-16194, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
MCF-7
1
2
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
BC-1
1
E-GEOD-2149
Capan1
1
E-MTAB-37
310 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (31 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-10797, E-MEXP-2034
mononuclear
2
E-GEOD-13987, E-GEOD-26672
primary human mammary epithelial cells
1
E-GEOD-29119
CD105+ endothelial
2
1
E-AFMX-5
culture-derived megakaryocytes
1
E-MEXP-70
Embryonic Kidney cell
1
E-GEOD-20677
56 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (54 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
melanoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
174 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-GEOD-5824, ... (18 experiments)

Factor Value U/D Experiments
4,5-dianilinophthalimide
2
1
E-GEOD-5258
vanadium pentoxide
1
E-GEOD-5339
hydrogen peroxide
1
E-GEOD-5339
LDL
1
1
E-GEOD-5741
TNF
1
E-GEOD-15205
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19246, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-GEOD-6236, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-20847

Genotype
studied in E-TABM-763, E-GEOD-22056, E-TABM-36, E-GEOD-2466, E-GEOD-17476, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (31 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-GEOD-923 ... (5 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Tumor size
studied in E-GEOD-4922

Processing time: 0.453 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM